Post-earnings recap
Reported
Tue, May 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report reflects CRISPR Therapeutics' ongoing challenges, particularly in achieving profitability. Despite missing on EPS, the stock saw a slight increase of 0.48%, likely driven by positive sentiments around their ongoing research efforts and pipeline developments. Investors may remain hopeful about future advancements in the company's technology.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about their ongoing projects. They reiterated their commitment to advancing their research initiatives.
Management highlighted ongoing advancements in their pipeline.
They emphasized the importance of continued research and development.
The team remains focused on long-term goals despite current challenges.